481 related articles for article (PubMed ID: 31276594)
1. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.
Cui J; Zhang Q; Song Q; Wang H; Dmitriev P; Sun MY; Cao X; Wang Y; Guo L; Indig IH; Rosenblum JS; Ji C; Cao D; Yang K; Gilbert MR; Yao Y; Zhuang Z
Neuro Oncol; 2019 Nov; 21(11):1436-1446. PubMed ID: 31276594
[TBL] [Abstract][Full Text] [Related]
2. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
3. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Lock FE; McDonald PC; Lou Y; Serrano I; Chafe SC; Ostlund C; Aparicio S; Winum JY; Supuran CT; Dedhar S
Oncogene; 2013 Oct; 32(44):5210-9. PubMed ID: 23208505
[TBL] [Abstract][Full Text] [Related]
4. Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model.
Song Y; Liu Q; Zuo T; Wei G; Jiao S
Cell Immunol; 2020 Jun; 352():104112. PubMed ID: 32305131
[TBL] [Abstract][Full Text] [Related]
5. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
Wang Y; Buck A; Piel B; Zerefa L; Murugan N; Coherd CD; Miklosi AG; Johal H; Bastos RN; Huang K; Ficial M; Laimon YN; Signoretti S; Zhong Z; Hoang SM; Kastrunes GM; Grimaud M; Fayed A; Yuan HC; Nguyen QD; Thai T; Ivanova EV; Paweletz CP; Wu MR; Choueiri TK; Wee JO; Freeman GJ; Barbie DA; Marasco WA
Mol Cancer; 2024 Mar; 23(1):56. PubMed ID: 38491381
[TBL] [Abstract][Full Text] [Related]
6. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.
Tafreshi NK; Lloyd MC; Proemsey JB; Bui MM; Kim J; Gillies RJ; Morse DL
Mol Imaging Biol; 2016 Apr; 18(2):219-31. PubMed ID: 26276155
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma.
Cui J; Wang H; Medina R; Zhang Q; Xu C; Indig IH; Zhou J; Song Q; Dmitriev P; Sun MY; Guo L; Wang Y; Rosenblum JS; Kovach JS; Gilbert MR; Zhuang Z
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935881
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.
Zhang Q; Xu J; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Wang Z; Fu Q; Zheng J
Oncol Rep; 2018 Dec; 40(6):3714-3724. PubMed ID: 30272343
[TBL] [Abstract][Full Text] [Related]
10. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
11. Dynamic surveillance of tamoxifen-resistance in ER-positive breast cancer by CAIX-targeted ultrasound imaging.
Li Y; Chen X; Zhou Z; Li Q; Westover KD; Wang M; Liu J; Zhang S; Zhang J; Xu B; Wei X
Cancer Med; 2020 Apr; 9(7):2414-2426. PubMed ID: 32048471
[TBL] [Abstract][Full Text] [Related]
12. CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target.
Drenckhan A; Freytag M; Supuran CT; Sauter G; Izbicki JR; Gros SJ
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1024-1033. PubMed ID: 29865880
[TBL] [Abstract][Full Text] [Related]
13. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
14. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
[TBL] [Abstract][Full Text] [Related]
15. Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.
Marks IS; Gardeen SS; Kurdziel SJ; Nicolaou ST; Woods JE; Kularatne SA; Low PS
Mol Pharm; 2018 Jun; 15(6):2289-2296. PubMed ID: 29715036
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells.
de Campos NSP; de Oliveira Beserra A; Pereira PHB; Chaves AS; Fonseca FLA; da Silva Medina T; Dos Santos TG; Wang Y; Marasco WA; Suarez ER
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628256
[TBL] [Abstract][Full Text] [Related]
17. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
18. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
20. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]